Optimization of risk stratification in localized prostate cancer

Alicia Katherine Morgans*

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

A 67-year-old retired engineering professor was found to have a prostate-specific antigen (PSA) level of 11 ng/mL on a screening test at his annual physical examination. A digital rectal examination revealed a nodule on the right side. He underwent a transrectal ultrasound-guided prostate biopsy that was notable for prostate adenocarcinoma, Gleason 3 + 4 = 7 (Gleason grade group 2; 30% Gleason 4 component) involving two cores (60% and 20% core involvement). A bone scan and pelvic computed tomography scan were negative for evidence of metastatic disease. (Should he undergo prostate magnetic resonance imaging? That seems rather common these days.) He was diagnosed with cT2b intermediate-risk localized prostate cancer (PCa) by National Comprehensive Cancer Network (NCCN) risk group and was seen in the multidisciplinary clinic to discuss management options (Table 1).

Original languageEnglish (US)
Pages (from-to)528-532
Number of pages5
JournalJournal of Clinical Oncology
Volume36
Issue number6
DOIs
StatePublished - Feb 20 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Optimization of risk stratification in localized prostate cancer'. Together they form a unique fingerprint.

  • Cite this